Patent · US Active

Gemella sanguinis as a biotherapeutic

US11344584B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Second Genome, Inc. · US

Inventors

Andrew Wonhee Han · Cambridge, US
Bernat Baeza Raja · South San Francisco, US
Shoko Kawana · South San Francisco, US
Mitsuko Lynn Yamamoto · South San Francisco, US
Karim Dabbagh · Brisbane, US
Todd Zachary DeSantis · Brisbane, US

Key dates

Filing date	Aug 6, 2018
Grant date	May 31, 2022
Priority date	—
Expiry date	Aug 6, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12R2001/01
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Gemella sanguinis and their uses in treating metabolic-related diseases or disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.